Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,743 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-11 · Sale · Disposed 22,417 · Balance 51,326 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 2 · 2026-06-12 · Sale · Disposed 12,583 · Balance 38,743 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Disposition to issuer · Disposed 1,375 · Balance 167,123 Row 2 · 2026-09-03 · Disposition to issuer · Disposed 167,123 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 110,665 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 124,962 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-03 · Disposition to issuer · Disposed 83,690 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2024 Filed Sep 7, 2024 00:03 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 787 | $48.06 | $37,823.22 |
DisclosureSEC source: 0001104659-24-097867 · tm2423502-2_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,793 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.80 to $48.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 04, 2024 Filed Sep 7, 2024 00:03 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,878 | $47.49 | $279,146.22 |
DisclosureSEC source: 0001104659-24-097867 · tm2423502-2_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,580 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.79 to $47.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2024 Filed Aug 10, 2024 00:05 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 670 | $42.56 | $28,515.20 |
DisclosureSEC source: 0001104659-24-087940 · tm2421174-2_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,458 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. Read SEC document |
| August 07, 2024 Filed Aug 10, 2024 00:05 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 142 | $41.09 | $5,834.78 |
DisclosureSEC source: 0001104659-24-087940 · tm2421174-2_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,128 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.08 to $41.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2024 Filed Aug 10, 2024 00:05 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 6,523 | $40.47 | $263,985.81 |
DisclosureSEC source: 0001104659-24-087940 · tm2421174-2_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,270 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2024 Filed Jul 6, 2024 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,143 | $38.16 | $81,776.88 |
DisclosureSEC source: 0001104659-24-078134 · tm2418983-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 294,793 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.85 to $38.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2024 Filed Jul 6, 2024 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 3,852 | $37.29 | $143,641.08 |
DisclosureSEC source: 0001104659-24-078134 · tm2418983-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,936 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.80 to $37.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 18, 2023 Filed Dec 21, 2023 01:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 175,345 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-23-127822 · tm2333399-3_4seq1.xml · derivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,345 Underlying: Common Stock · 175,345 shares Expires 2033-12-18 F1 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.